SCHEMBL17092909

SCHEMBL17092909

NC1CC1c1c[c]ccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 13/20 0.58
MAOB P27338 10/20 0.58
MAOA P21397 7/20 0.58
CYP2C19 P33261 4/20 0.58
CYP2B6 P20813 3/20 0.58
CYP1A2 P05177 2/20 0.58
CYP2D6 P10635 2/20 0.58
CYP2C9 P11712 2/20 0.58
LMNA P02545 2/20 0.58
TAAR1 Q96RJ0 2/20 0.58
CYP2A6 P11509 2/20 0.58
KCNH2 Q12809 2/20 0.58
RCOR1 Q9UKL0 2/20 0.58
CYP3A4 P08684 1/20 0.58
HTR1A P08908 1/20 0.58
ADRA2A P08913 1/20 0.58
SLC6A2 P23975 1/20 0.58
HTR2C P28335 1/20 0.58
ADRA1A P35348 1/20 0.58
DRD3 P35462 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17092910 1.00 KDM1A (0.58) KDM1AMAOBMAOACYP2C19CYP2B6
SCHEMBL27008280 0.78 MAOB (0.32) KDM1AMAOBMAOACYP2C19CYP2B6
SCHEMBL16268038 0.75 KDM1A (0.58) KDM1AMAOBMAOACYP2C19CYP2B6
SCHEMBL16268040 0.75 KDM1A (0.58) KDM1AMAOBMAOACYP2C19CYP2B6
(+)-Tranylcypromine SCHEMBL1649712 0.74 KDM1A (1.00) KDM1AMAOBMAOACYP2C19CYP2B6
(+)-Tranylcypromine SCHEMBL4740285 0.74 KDM1A (1.00) KDM1AMAOBMAOACYP2C19CYP2B6
(+)-Tranylcypromine SCHEMBL1720497 0.74 KDM1A (1.00) KDM1AMAOBMAOACYP2C19CYP2B6
(+)-Tranylcypromine SCHEMBL40651 0.74 KDM1A (1.00) KDM1AMAOBMAOACYP2C19CYP2B6
(+)-Tranylcypromine SCHEMBL13785162 0.74 KDM1A (1.00) KDM1AMAOBMAOACYP2C19CYP2B6
(+)-Tranylcypromine SCHEMBL34339 0.74 KDM1A (1.00) KDM1AMAOBMAOACYP2C19CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2907802-B1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 EP disclosed
US-9751885-B2 Cyclopropanamine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-05 US disclosed
US-20150266881-A1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266881-A1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF BHMT, HNMT, KDM1A KDM1A 3/4885MAOB 27/4885MAOA 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.